Based in Switzerland, and listed on the Swiss Stock Exchange, Evolva utilises biosynthetic and evolutionary technologies (green chemistry) to create and optimise small molecule compounds and their production routes for consumer healthcare and nutrition as well as in pharmaceuticals via both collaborations and proprietary programs.
CEO of Evolva, Neil Goldsmith, has headed up the management team since April 2004. He has more than 22 years of experience in building successful biotech companies, including co-founding TopoTarget A/S (listed on the Copenhagen exchange) and Personal Chemistry AB (now called Biotage AB and listed on the Stockholm exchange). Goldsmith was also the CEO of Auda Pharmaceuticals (acquired by Phytera Inc.), GX Biosystems and PNA Diagnostics (acquired by Boehringer Mannheim).
The Chief Scientific Officer (CSO) is Prof. Dr. Jutta Heim. Before joining Evolva in 2009, Dr. Heim was the Chief Scientific Officer of Basilea Pharmaceutica AG, a Swiss biopharmaceutical company, where she was in charge of all anti-infective, dermatology and oncology discovery activities. She was also with Ciba-Geigy/Novartis, involved in the successful development and launch of biopharmaceutical anti-thrombotic and fibrinolytic products, initiated a molecular genetics department in oncology and became Novartis' senior scientific expert in molecular biology and a member of the company’s Research Management Board.